New steps have been taken in Chile that will benefit patients who need high cost treatments. Piga Fernández, LRG Global Consultant in Chile, together with representatives of 26 patient organizations has been working on [...]
On Wednesday, February 11, the Life Raft Group’s state leaders had their first opportunity to gather virtually and to discuss the best strategies for bringing together and building a support community for patients and [...]
Joyce Elaine O’Shea, aged 61, passed away at home in Aptos, California on Thursday, February 26, 2015. She courageously fought cancer, never losing her spirit of faith. Born September 13, 1953 in San Jose, [...]
Louise Leonard, 78, of Girard, Ohio, beloved wife, mother, grandmother and friend passed away on February 2, 2015 surrounded by her loving family. Born November 22, 1936 in Youngstown, Ohio, the daughter of the [...]
I had a “surprise” diagnosis of GIST in April, 2009, and thanks to the Life Raft Group and its knowledge and an excellent surgeon along with the assistance of Gleevec for about five years, [...]
In a recent study led by Danielle A Bischof, MD of Johns Hopkins and published in JAMA Surgery, the authors propose a new way of estimating disease-free survival for GIST patients – Conditional Disease-free Survival [...]
A recent roundtable discussion at the National Comprehensive Cancer Network’s (NCCN) 20th Annual Conference opened up a discussion on treatment costs and introduced the proposed use of evidence blocks to compare treatments. Currently, the [...]
Cancer patients are surviving longer thanks to breakthrough treatments like targeted therapies. With the additional longevity, however, is the responsibility to consider other health issues that may manifest, either due to treatments such as [...]
A Phase II clinical trial comparing Imatinib alternated with Regorafenib to Imatinib alone is currently underway and recruiting in Australia. The trial, sponsored by the Australasian Gastro-Intestinal Trials Group, looks to examine the feasibility of [...]
Novartis Pharmaceuticals recently received FDA approval for panobinostat, a blood cancer drug that targets multiple myeloma. This was a surprising ruling, as it was a turnaround from last year’s Oncologic Drugs Advisory Committee’s 5-2 [...]
